Hypofibrinolytic dysregulations can be detected of frozen plasma samples using viscoelastic testing

Introduction: Congenital and acquired dysregulations in fibrinolysis system can lead to hyperfibrinolysis (increased bleeding) or hypofibrinolysis (increased thrombosis), with potential for multi-organ failure. Traditional laboratory methods provide limited insight onto the function of the fibrinolysis system. Viscoelastic testing (VT) offers rapid and comprehensive assessment of both coagulation and fibrinolysis systems. This study evaluates the performance of VT to test frozen plasma samples spiked into healthy whole blood.

Method: In an observational single-center study,15 patients with suspected fibrinolytic disorders were included. Citrated whole blood and platelet-poor plasma (PPP) samples were collected. Whole blood samples were tested immediately using thromboelastography (TE) via EX- and TPA-test, whereas PPP were frozen, and analyzed later using spike-in experimental setting. In brief, frozen PPP from patients were thawed up and reconstituted into healthy plasma-depleted blood samples. A global fibrinolysis capacity (GFC) assay using a Lysis Timer was performed to confirm fibrinolysis disruption in patient plasma samples.

Results: First, the validation of the spike-in approach with 20 healthy donors showed significant correlation in lysis time (LT) between primary results of healthy whole blood samples and reconstituted PPP-spike-in samples (r=0.67, p=0.001). Moreover, the lysis time of the original whole blood of the patients correlates with the spike-in samples (r=0.63; p=0.01). The spike-in samples of hypofibrinolytic patients showed an increase in lysis time compared to spike-in of healthy controls (LT in TPA-test: 218.3±39.5 sec vs. 165.7±16.4 sec , p<0.0001). The Lysis Timer assay and ELISA testing supported these findings, suggesting a plasmatic factor, likely PAI-1, as the cause. Interestingly, shorter lysis time was observed in spike-in samples with hypofibrinolytic PPP compared to original measurement in whole blood samples (LT in original TPA-test: 218.3±39.5 sec vs. 391.5±333.0 sec, respectively, p<0.0001). These data suggest hypofibrinolysis in patients with thrombosis might be mediated by dysregulation of plasmatic as well as cellular coagulation systems.

Conclusion: The spike-in approach for thromboelastography is effective for retrospective hypofibrinolysis diagnosis especially in laboratories with no immediate access to viscoelastography [1] [2] [3] [4] [5] [6] [7].

Our data suggest that a plasmatic factor and a cellular factor might be responsible for the hypofibrinolytic activity. To prove this, further investigations are needed to identify the role of cellular components in the fibrinolysis system.

Publikationsverlauf

Artikel online veröffentlicht:
13. Februar 2025

• References

• 1 Moore HB.. Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States. Semin Thromb Hemost 2023; 49: 433-443
• 2 Hvas CL, Larsen JB.. The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment. Int J Mol Sci. 2023: 24
• 3 Hammer S, Haberle H, Schlensak C. et al. Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19. Thromb Haemost 2021; 121: 1417-1426
• 4 Zlamal J, Althaus K, Jaffal H. et al. Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. Blood Adv. 2022
• 5 Althaus K, Moller P, Uzun G. et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021; 106: 2170-2179
• 6 Althaus K, Marini I, Zlamal J. et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood 2021; 137
• 7 Driessen A, Schafer N, Bauerfeind U. et al. Functional capacity of reconstituted blood in 1:1:1 versus 3:1:1 ratios: a thrombelastometry study. Scand J Trauma Resusc Emerg Med. 2015 23.